+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global HERG Screening Market Size was valued at USD 0.7 Billion in 2022. The HERG Screening market Application is projected to grow from USD 1.2 Billion in 2023 to USD 2.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.70% during the forecast period (2023 - 2032). The rising approval of innovative drugs and the rise in heart disease prevalence, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
The market is anticipated to expand as heart disease prevalence and the number of heart condition patients both rise. Increased R&D activity in support of new product releases also contributes to the market's expansion. Additionally, it is anticipated that an increase in the approvals of novel drug entities will contribute to the market's expansion. The development of treatments for diseases and disorders and the rise in demand for medication formulations both contribute to the market's expansion. Additionally, growing prospects for the development of the HERG screening market are being created by growing difficulties in generating biotechnological or pharmaceutical products based on the application.
There has been a strong demand for screening the substances used in medicine manufacture due to the rise in cardiotoxicity occurrences. HERG screenings may be superior to traditional testing procedures in a number of ways, including being safer and more effective when used on medicines. Patients with pre-existing heart issues are increasingly experiencing negative side effects from cardiac medications. Patients who have undergone cardiac surgery or cancer therapy are more likely to have cardiotoxicity. As a result, there is a growing need for tools and services that facilitate effective cardiotoxicity screening. Cardiotoxicity makes it difficult for the heart to perform daily tasks and pump blood throughout the body. As a result, cardiotoxicity increases the likelihood of cardiomyopathy, which impairs the heart's ability to pump blood.
The leading cause of death for both men and women worldwide is heart disease. Every 40 seconds, an American will suffer a myocardial infarction, claims the American College of Cardiology. According to emergency medical services, 356,461 Americans experienced cardiac arrest outside of a hospital in 2017; emergency medical services treatment was initiated in 52% of those cases. Only 18.7% of the patients had a cardiac rhythm that could be shockable by an AED, ventricular fibrillation, or ventricular tachycardia at the beginning of their treatment. Adults had a hospital discharge survival rate of 10.4%, and 8.4% had satisfactory functional status.
The prevalence of cardiovascular diseases can be attributed to sedentary lifestyles and common risk factors like hypertension, which can range from 28% in the United Arab Emirates to 41% in Libya and Morocco, diabetes, which can range from 4% in the Islamic Republic of Iran to 19% in Sudan, and hypercholesterolemia, which can range from 14% in Lebanon to 52% in the Islamic Republic of Iran. As a result of the increase in heart disease, the market for drug discovery will grow, supporting the growth of the HERG screening market. Thus, driving the HERG Screening market revenue.
The global HERG Screening market segmentation, based on Type, includes Gene KCNH2 and Mutant KCNH2. Gene KCNH2 segment dominated the global market in 2022. This channel is especially important for the generation and transmission of electrical impulses as it is in charge of removing positively charged potassium atoms from the cells. This is so that it can move the atoms of potassium. The KCNH2 gene is in charge of controlling and supplying the necessary instructions for the production of potassium channels. The main reason causing the ultimate emergence of cardiac arrhythmia was the KCNH2 mutation.
The global HERG Screening market segmentation, based on Ion Channel, includes Voltage Gated and Ligand Gated. Voltage Gated segment dominated the global HERG Screening market in 2022. The members of the voltage-gated ion channel family that regulate the open and closed states of the cell membrane potential include Na+, Ca+, and K+. The ionic gradients required for regular cell activity are maintained by these channels in a variety of cell types, including neurons, heart muscle, and skeletal muscle. The movement of ions across cell membranes is tightly regulated by these channels.
The global HERG Screening market segmentation, based on Application, includes Antiarrhythmic, Antipsychotic, Antibiotics, and Others. Antiarrhythmic based segment dominated the global market in 2022. Antiarrhythmic medications are used to treat symptomatic tachycardias and premature beats. These can be administered intravenously in an emergency or orally for long-term treatment. These drugs either prevent aberrant pacemaker tissue firing or reduce the speed at which impulses are transmitted in tissues that conduct too quickly or engage in reentry. The use of these assays for arrhythmia treatment, scientific investigations into the safety and effectiveness of HERG screening, and an increase in cardiovascular diseases globally are all factors propelling the market's growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America HERG Screening Market dominated this market in 2022 (45.80%). Every 40 seconds, a citizen of the United States will experience a myocardial infarction, according to the American College of Cardiology. In 2017, 356,460 Americans went through an out-of-hospital cardiac arrest, and in 52% of those cases, emergency medical services were called. Further, the U.S. HERG Screening market held the largest market share, and the Canada HERG Screening market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
Europe HERG Screening market accounted for the healthy market share in 2022. Europe's western and eastern regions make up the majority of the market for HERG screening and are both regarded as major contributors. Further, the German HERG Screening market held the largest market share, and the U.K HERG Screening market was the fastest growing market in the European region.
The Asia Pacific HERG Screening market is expected to register significant growth from 2023 to 2032. A significant portion of the people in the area have chronic heart conditions, and the incidence of inflammatory disorders is rising quickly as well. Moreover, China’s HERG Screening market held the largest market share, and the Indian HERG Screening market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the HERG Screening market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, HERG Screening Industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global HERG Screening Industry to benefit clients and increase the market sector. In recent years, the HERG Screening Industry has offered some of the most significant advantages to medicine. Major players in the HERG Screening market, including Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, and Aurora Biomed, are attempting to increase market demand by investing in research and development operations.
A contract research organisation (CRO), Charles River Laboratories International Inc. (Charles River), offers crucial goods and services to hasten analysis, drug discovery, and development. It provides a range of services for basic research, medication discovery, and safety evaluation. Additionally, the business provides staffing, operational, and manufacturing assistance. It offers remedies targeted at treating diseases of the heart, brain, metabolism, inflammatory, ophthalmological, respiratory, musculoskeletal, and oncological systems. Leading hospitals and academic institutions as well as government organisations, pharmaceutical and biotechnology businesses, and other clients are served by Charles River. The US city of Wilmington, Massachusetts, is home to Charles River's headquarters.
A life sciences business called Eurofins Scientific SE (Eurofins) offers clients in numerous industries analytical testing services. The business provides forensic services, environmental testing, agroscience services, biopharma services, pharma discovery services, pharma early development, pharma central laboratory, biopharma product testing, and product testing. Its analytical techniques aid in determining the purity, authenticity, and safety of biological products and substances. To provide a variety of services, it makes use of its expertise in information technology and logistics. The corporation has operations in South America, the Middle East, Asia Pacific, Europe, and North America. The headquarters of Eurofins are in Luxembourg. A leader in drug discovery products and services, from target identification and lead discovery to preclinical and beyond, Discover X was acquired by Eurofins Scientific in July 2017.
• Charles River Laboratories
• Eurofins Scientific
• Merck KGaA
• Cyprotex Limited
• BSYS GmbH
• Creative bioarray
• Metrion biosciences
• Aurora Biomed
March 2020: An alliance was formed between Charles River Laboratories and Deciphex, a pioneer in preclinical digital pathology software-as-a-service. The organisations will collaborate to co-develop deep learning-enabled technologies to facilitate expedited pathology analytics, and Charles River will serve as the sole contract research organisation providing the Patholytix preclinical solution to clients.
· Gene KCNH2
· Mutant KCNH2
· Voltage Gated
· Ligand Gated
· Antiarrhythmic
· Antipsychotic
· Antibiotics
· Others
· North America
- US
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
Report Scope
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 0.7 Billion |
|
Market Size 2023 |
USD 1.2 Billion |
|
Market Size 2032 |
USD 2.8 Billion |
|
Compound Annual Growth Rate (CAGR) |
12.70% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Type, Ion Channel, Application, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, and Aurora Biomed |
|
Key Market Opportunities |
Untapped regional markets |
|
Key Market Dynamics |
Increasing novel drug approvals and the growing prevalence of heart diseases |
The global HERG Screening market was valued at USD 0.7 billion in 2022, and it is estimated to reach USD 2.8 billion by 2032.
The global market is projected to grow at a CAGR of 12.70% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, and Aurora Biomed
The Gene KCNH2 Type dominated the market in 2022.
The Voltage Gated Ion Channel had the largest share in the global market.
Report Code :
RL6552
Published on :
Aug 2023
Request a Free Sample Report
Speak to Analyst